Microbiota modulation in disorders of gut-brain interaction
Digestive and Liver Disease · 2024
DOI: 10.1016/j.dld.2024.05.004 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Digestive and Liver Disease, 2024. Verfasst von Giovanni Marasco und 5 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy; Department of Medical and Surgical Sciences, University of Bologna, Italy. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Probiotics, Prebiotics, Brain-Gut Axis. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 129 Literaturangaben.
Abstract (Originalsprache)
Disorders of gut-brain interaction (DGBI) are common chronic conditions characterized by persistent and recurring gastrointestinal symptoms triggered by several pathophysiological factors, including an altered gut microbiota. The most common DGBI are irritable bowel syndrome (IBS), functional constipation (FC) and functional dyspepsia (FD). Recently, a deep understanding of the role of the gut microbiota in these diseases was possible due to multi-omics methods capable to provide a comprehensive assessment. Most of the therapies recommended for these patients, can modulate the gut microbiota such as diet, prebiotics, probiotics and non-absorbable antibiotics, which were shown to be safe and effective. Since patients complain symptoms after food ingestion, diet represents the first line therapeutic approach. Avoiding dietary fat and fermentable oligosaccharides, disaccharides, monosaccharides, and polyols, and increasing the number of soluble fibers represent the therapeutic choices for FD, IBS and FC respectively. Probiotics, as a category, have been employed with good results in all the abovementioned DGBI. Rifaximin has been shown to be useful in the context of bowel related disorders, although a recent trial showed positive results for FD. Fecal microbiota transplantation has been tested for IBS and FC with promising results. In this review, we will briefly summarize the current understanding on dysbiosis and discuss microbiota modulation strategies to treat patients with DGBI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy; Department of Medical and Surgical Sciences, University of Bologna, Italy.
- IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy.
- IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy; Department of Medical and Surgical Sciences, University of Bologna, Italy. Electronic address: giovanni.barbara@unibo.it.
Zitieren
APA
Marasco, G., Cremon, C., Barbaro, M. R., Bianco, F., Stanghellini, V., & Barbara, G. (2024). Microbiota modulation in disorders of gut-brain interaction. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2024.05.004
Vancouver
Marasco G, Cremon C, Barbaro MR, Bianco F, Stanghellini V, Barbara G. Microbiota modulation in disorders of gut-brain interaction. Digestive and Liver Disease. 2024. doi:10.1016/j.dld.2024.05.004
BibTeX
@article{Marasco2024,
author = {Marasco, Giovanni and Cremon, Cesare and Barbaro, Maria Raffaella and Bianco, Francesca and Stanghellini, Vincenzo and Barbara, Giovanni},
title = {Microbiota modulation in disorders of gut-brain interaction},
journal = {Digestive and Liver Disease},
year = {2024},
doi = {10.1016/j.dld.2024.05.004}
}
EUVIMED